Utah Medical Products, Inc. (UTMD) reported a decline in financial performance for the first quarter of 2026, with net sales totaling $8.72 million, a decrease of 10.2% from $9.71 million in the same period of 2025. The company's gross profit also fell to $5.28 million, down 4.6% from $5.54 million year-over-year. Operating income decreased by 18.7% to $2.57 million, while net income was reported at $2.60 million, reflecting a 14.4% decline from $3.04 million in the prior year. Earnings per share (EPS) decreased to $0.82 from $0.92, marking an 11% drop.
The decline in revenue was attributed primarily to the loss of sales from UTMD's largest distributor of blood pressure monitoring devices in China, which accounted for a significant portion of the decrease. Additionally, sales outside the U.S. fell by 23.4%, with the absence of sales to the former distributor contributing to this decline. Domestic sales remained relatively stable, with a slight decrease of 0.4%. The company noted that while overall sales were lower, the gross profit margin improved to 60.6% from 57.0% due to a favorable product mix and adjustments to standard costs.
In terms of operational developments, UTMD's total current assets increased to $100.38 million as of March 31, 2026, up from $97.74 million at the end of 2025. The company maintained a strong balance sheet with no debt, and stockholders' equity rose to $120.37 million, an increase from $119.27 million. The company also repurchased 2,196 shares during the quarter, reflecting its commitment to returning value to shareholders. The total number of shares outstanding decreased to 3.18 million from 3.19 million at the end of 2025.
Looking ahead, UTMD's management remains focused on several strategic objectives for 2026, including regaining international business affected by trade policies, introducing new products, and resolving ongoing product liability lawsuits. The company aims to leverage its cash generation capabilities to continue paying dividends and repurchasing shares when deemed appropriate. Management expressed optimism about future growth opportunities, particularly in the biopharmaceutical sector, while remaining vigilant for potential acquisitions that could enhance revenue and earnings per share growth.
About UTAH MEDICAL PRODUCTS INC
Utah Medical Products, Inc. designs and manufactures high-quality, safety-focused medical devices primarily for critical care, obstetrics, neonatal intensive care, gynecology, and urology. Its core offerings include fetal monitoring accessories, neonatal catheters, gynecological electrosurgical tools, and contraceptive devices like the Filshie clip. The company serves global markets through direct sales, distributors, and OEM partnerships, emphasizing clinical utility, reliability, and regulatory compliance.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.